Mpex Pharmaceuticals - Specializing in New Antibiotics for Serious Infections and Bacterial Resistance
    Home Research Team News Employment Contact

 


Research & Development

Mpex Pharmaceutical's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex has advanced its lead aerosol antibiotic product Aeroquin (MP-376) through phase 2 clinical development, and its EPI program into lead optimization.

MP-376 Clinical Program

Efflux Pump Inhibitor Program